Graffinity and Eli Lilly sign collaboration agreement

German drug discovery company Graffinity Pharmaceuticals, which specialises in chemical genomics, has signed a collaboration agreement with Eli Lilly, under the terms of which Lilly will provide a selection of its drug targets to Graffinity. The Heidelberg-based company will use its proprietary drug discovery platform, which is centred on chemical microarrays, drug fragment libraries, and label-free imaging of protein-ligand interactions, to identify novel small molecule hit compounds against a selection of Lilly's therapeutic targets.

'Novel screening and chemistry technologies that can work across a range of targets are a vital part of modern drug discovery,' said Victor Matassa, vice president of r&d at Graffinity.